Citigroup, JPMorgan And 3 Stocks To Watch Heading Into Friday
Portfolio Pulse from Avi Kapoor
Citigroup, JPMorgan, Argan, PaxMedica, and Wells Fargo are stocks to watch due to earnings reports and significant after-hours trading movements. Citigroup and Wells Fargo are anticipated to report their quarterly earnings, with Citigroup expected to show a decrease compared to the previous year. Argan reported better-than-expected Q4 results, leading to a 7.4% increase in its stock price. JPMorgan is also expected to release its earnings, with a slight increase in its stock price in after-hours trading. PaxMedica announced the completion of pivotal batches for PAX-101, causing a 116.1% surge in its stock price.
April 12, 2024 | 7:00 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup is expected to report a decrease in earnings per share compared to the previous year, with a slight increase in after-hours trading.
The expected decrease in earnings per share may concern investors, but the slight increase in after-hours trading suggests a neutral short-term impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
JPMorgan is expected to post quarterly earnings, with a slight increase in its stock price in after-hours trading.
The anticipation of earnings and the slight increase in after-hours trading suggest a neutral short-term impact on JPMorgan's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
Wells Fargo is expected to report quarterly earnings, with a minor slip in its stock price in after-hours trading.
The expected earnings report and minor slip in stock price suggest a neutral short-term impact on Wells Fargo's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Argan reported better-than-expected Q4 results, leading to a 7.4% increase in its stock price in after-hours trading.
The positive earnings surprise and subsequent stock price surge indicate a likely short-term positive impact on Argan's stock.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 95
POSITIVE IMPACT
PaxMedica announced the completion of pivotal batches for PAX-101, causing a 116.1% surge in its stock price.
The significant stock price surge following the announcement indicates a strong short-term positive impact on PaxMedica's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100